Ionis Pharmaceuticals, Inc.
āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™

Ionis Pharmaceuticals Inc 🧙

168
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

If you want not to miss ideas like this one,ðŸŽŊ subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! ðŸĪ“ Interested to study how to analyze charts, follow me!

āļ„āļģāļˆāļģāļāļąāļ”āļŠāļīāļ—āļ˜āļīāđŒāļ„āļ§āļēāļĄāļĢāļąāļšāļœāļīāļ”āļŠāļ­āļš

āļ‚āđ‰āļ­āļĄāļđāļĨāđāļĨāļ°āļšāļ—āļ„āļ§āļēāļĄāđ„āļĄāđˆāđ„āļ”āđ‰āļĄāļĩāļ§āļąāļ•āļ–āļļāļ›āļĢāļ°āļŠāļ‡āļ„āđŒāđ€āļžāļ·āđˆāļ­āļāđˆāļ­āđƒāļŦāđ‰āđ€āļāļīāļ”āļāļīāļˆāļāļĢāļĢāļĄāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™, āļāļēāļĢāļĨāļ‡āļ—āļļāļ™, āļāļēāļĢāļ‹āļ·āđ‰āļ­āļ‚āļēāļĒ, āļ‚āđ‰āļ­āđ€āļŠāļ™āļ­āđāļ™āļ° āļŦāļĢāļ·āļ­āļ„āļģāđāļ™āļ°āļ™āļģāļ›āļĢāļ°āđ€āļ āļ—āļ­āļ·āđˆāļ™ āđ† āļ—āļĩāđˆāđƒāļŦāđ‰āļŦāļĢāļ·āļ­āļĢāļąāļšāļĢāļ­āļ‡āđ‚āļ”āļĒ TradingView āļ­āđˆāļēāļ™āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ—āļĩāđˆ āļ‚āđ‰āļ­āļāļģāļŦāļ™āļ”āļāļēāļĢāđƒāļŠāđ‰āļ‡āļēāļ™